Biological therapy in polymyalgia rheumatica

References

• Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Polymyalgia rheumatica. Lancet. 2023 Oct 10;S0140-6736(23):01310–7. doi: 10.1016/S0140-6736(23)01310-7
   Google Scholar
• González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. Lancet. 2017 Oct 7;390(10103):1700–1712. doi: 10.1016/S0140-6736(17)31825-1
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Semin Arthritis Rheum. 2017 Oct;47(2):253–256. doi: 10.1016/j.semarthrit.2017.04.001
   PubMed Web of Science ®Google Scholar
• Raheel S, Shbeeb I, Crowson CS, et al. Epidemiology of Polymyalgia Rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1282–1285. doi: 10.1002/acr.23132
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484–492. doi: 10.1136/annrheumdis-2011-200329
   PubMed Web of Science ®Google Scholar
• Wendling D, Blagosklonov O, Boulahdour H, et al. Positron emission tomography: the ideal tool in polymyalgia rheumatica? Joint Bone Spine. 2014 Oct;81(5):381–383. doi: 10.1016/j.jbspin.2014.04.007
   PubMed Web of Science ®Google Scholar
• Sondag M, Guillot X, Verhoeven F, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatology (Oxford). 2016 Aug;55(8):1452–1457. doi: 10.1093/rheumatology/kew202
   PubMed Web of Science ®Google Scholar
• Tomelleri A, van der Geest KSM, Khurshid MA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat Rev Rheumatol. 2023 Jul;19(7):446–459. doi: 10.1038/s41584-023-00976-8
   PubMed Web of Science ®Google Scholar
• De Miguel E, Macchioni P, Conticini E, et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford). kead189. 2023 May 2. doi: 10.1093/rheumatology/kead189
   PubMed Web of Science ®Google Scholar
• Hemmig AK, Gozzoli D, Werlen L, et al. Subclinical giant cell arteritis in new onset polymyalgia rheumatica a systematic review and meta-analysis of individual patient data. Semin Arthritis Rheum. 2022 Aug;55:152017
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799–1807. doi: 10.1136/annrheumdis-2015-207492
   PubMed Web of Science ®Google Scholar
• Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2023 Feb;24:ard-2022–223429
   Google Scholar
• Partington R, Helliwell T, Muller S, et al. Comorbidities in polymyalgia rheumatica: a systematic review. Arthritis Res Ther. 2018 Nov 20;20(1):258. doi: 10.1186/s13075-018-1757-y
   PubMedGoogle Scholar
• Partington R, Muller S, Mallen CD, et al. Comorbidities in patients with polymyalgia rheumatica prior to and following diagnosis: a case control and cohort study. Semin Arthritis Rheum. 2020 Aug;50(4):663–672. doi: 10.1016/j.semarthrit.2020.05.003
   PubMed Web of Science ®Google Scholar
• Sattui SE, Jannat-Khah D, Lally L, et al. Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia. Rheumatology (Oxford). 2022 Nov 2;61(11):4455–4464. doi: 10.1093/rheumatology/keac050
   PubMed Web of Science ®Google Scholar
• Mackie SL, Hensor EM, Haugeberg G, et al. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford). 2010 Apr;49(4):716–722. doi: 10.1093/rheumatology/kep395
   PubMed Web of Science ®Google Scholar
• Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41(1):19–31. doi: 10.1007/s10067-021-05819-z
   PubMed Web of Science ®Google Scholar
• Perricone C, Cafaro G, Fiumicelli E, et al. Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica. Clin Exp Med. 2022 Dec 24;23(7):3391–3397. doi: 10.1007/s10238-022-00976-0
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996 Apr;55(4):218–223. doi: 10.1136/ard.55.4.218
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004 Oct 5;141(7):493–500. doi: 10.7326/0003-4819-141-7-200410050-00005
   PubMed Web of Science ®Google Scholar
• Ghosh N, Couette N, van Binsbergen WH, et al. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a scoping review by the OMERACT irAE working group. Semin Arthritis Rheum. 2023 Feb;58:152110
   PubMed Web of Science ®Google Scholar
• Carvajal Alegria G, Boukhlal S, Cornec D, et al. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev. 2020 Nov;19(11):102670. doi: 10.1016/j.autrev.2020.102670
   PubMed Web of Science ®Google Scholar
• Coskun Benlidayi I. Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review. Clin Rheumatol. 2023 Jul 20. doi:10.1007/s10067-023-06708-3
   Web of Science ®Google Scholar
• Marsman DE, den Broeder N, Boers N, et al. Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica? Clin Exp Rheumatol. 2021 Jan;39(1):32–37. doi: 10.55563/clinexprheumatol/gdps1r
   PubMed Web of Science ®Google Scholar
• Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004 Oct;63(10):1279–1283. doi: 10.1136/ard.2003.011379
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Saraux L, Berthelot JM, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatology (Oxford). 2018 Apr 1;57(4):666–670. doi: 10.1093/rheumatology/kex477
   PubMed Web of Science ®Google Scholar
• Manzo C, Hysa E, Castagna A, et al. The role of tumor necrosis factor alpha antagonists (anti TNF-α) in personalized treatment of patients with isolated Polymyalgia Rheumatica (PMR): past and possible future scenarios. J Pers Med. 2022 Feb 22;12(3):329. doi: 10.3390/jpm12030329
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol. 2003 Apr;30(4):760–763.
   PubMed Web of Science ®Google Scholar
• Catanoso MG, Macchioni P, Boiardi L, et al. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum. 2007 Dec 15;57(8):1514–1519. doi: 10.1002/art.23095
   PubMedGoogle Scholar
• Aikawa NE, Pereira RM, Lage L, et al. Anti-TNF therapy for polymyalgia rheumatica: report of 99 cases and review of the literature. Clin Rheumatol. 2012 Mar;31(3):575–579. doi: 10.1007/s10067-011-1914-z
   PubMed Web of Science ®Google Scholar
• Migliore A, Massafra U, Carloni E, et al. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci. 2005 Nov;9(6):373–378.
   PubMedGoogle Scholar
• Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007 May 1;146(9):631–639. doi: 10.7326/0003-4819-146-9-200705010-00005
   PubMed Web of Science ®Google Scholar
• Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176. doi: 10.1186/ar3140
   PubMed Web of Science ®Google Scholar
• Corrao S, Pistone G, Scaglione R, et al. Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol. 2009 Jan;28(1):89–92. doi: 10.1007/s10067-008-1026-6
   PubMed Web of Science ®Google Scholar
• Hagihara K, Kawase I, Tanaka T, et al. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010 May;37(5):1075–1076. doi: 10.3899/jrheum.091185
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1720–1729. doi: 10.1002/acr.21750
   PubMed Web of Science ®Google Scholar
• Al Rashidi A, Hegazi MO, Mohammad SA, et al. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol. 2013 Oct;19(7):400–401. doi: 10.1097/RHU.0b013e3182a6aa0e
   PubMed Web of Science ®Google Scholar
• Macchioni P, Boiardi L, Catanoso M, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013 Aug;43(1):113–118. doi: 10.1016/j.semarthrit.2013.01.003
   PubMed Web of Science ®Google Scholar
• Izumi K, Kuda H, Ushikubo M, et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open. 2015 Nov 27;1(1):e000162. doi: 10.1136/rmdopen-2015-000162
   PubMedGoogle Scholar
• Toussirot É, Martin A, Soubrier M, et al. Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: a multicenter open-label study. J Rheumatol. 2016 Jan;43(1):249–250. doi: 10.3899/jrheum.150599
   PubMed Web of Science ®Google Scholar
• Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol. 2016 May;35(5):1367–1375. doi: 10.1007/s10067-014-2650-y
   PubMed Web of Science ®Google Scholar
• Camellino D, Soldano S, Cutolo M, et al. Dissecting the inflammatory response in polymyalgia rheumatica: the relative role of IL-6 and its inhibition. Rheumatol Int. 2018 Sep;38(9):1699–1704. doi: 10.1007/s00296-018-4086-1
   PubMed Web of Science ®Google Scholar
• Izumi K, Murata O, Higashida-Konishi M, et al. Steroid-sparing effect of tocilizumab and methotrexate in patients with Polymyalgia Rheumatica: a retrospective cohort study. J Clin Med. 2021 Jun 30;10(13):2948. doi: 10.3390/jcm10132948
   PubMed Web of Science ®Google Scholar
• Assaraf M, Chevet B, Wendling D, et al. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicenter retrospective observational study. Rheumatology (Oxford). 2023 Aug 21;kead426. doi: 10.1093/rheumatology/kead426
   PubMedGoogle Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016 Aug;75(8):1506–1510. doi: 10.1136/annrheumdis-2015-208742
   PubMed Web of Science ®Google Scholar
• Palard-Novello X, Querellou S, Gouillou M, et al. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):773–779. doi: 10.1007/s00259-015-3287-z
   PubMed Web of Science ®Google Scholar
• Huwart A, Garrigues F, Jousse-Joulin S, et al. Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. Arthritis Res Ther. 2018 Jan 25;20(1):11. doi: 10.1186/s13075-017-1499-2
   PubMedGoogle Scholar
• Carvajal Alegria G, Garrigues F, Bettacchioli E, et al. Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine. 2021 May;88(3):105117. doi: 10.1016/j.jbspin.2020.105117
   PubMed Web of Science ®Google Scholar
• Lally L, Forbess L, Hatzis C, et al. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis & Rheumat. 2016 Oct;68(10):2550–2554. doi: 10.1002/art.39740
   PubMed Web of Science ®Google Scholar
• Chino K, Kondo T, Sakai R, et al. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Of Rheum Dis. 2019 Dec;22(12):2151–2157. doi: 10.1111/1756-185X.13723
   PubMed Web of Science ®Google Scholar
• Spiera R, Unizony SH, Bao M, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum. 2021 Apr;51(2):469–476. doi: 10.1016/j.semarthrit.2021.03.006
   PubMed Web of Science ®Google Scholar
• Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. Ann Rheum Dis. 2022 Jun;81(6):838–844. doi: 10.1136/annrheumdis-2021-221126
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving Glucocorticoid therapy: a randomized clinical trial. JAMA. 2022 Sep 20;328(11):1053–1062. doi: 10.1001/jama.2022.15459
   PubMed Web of Science ®Google Scholar
• Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med. 2023 Oct 5;389(14):1263–1272. doi: 10.1056/NEJMoa2303452
   PubMed Web of Science ®Google Scholar
• Marsman DE, Broeder ND, Hoogen FHJ, et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. The Lancet Rheumatology. 2021;3(11):e758–e766. doi: 10.1016/S2665-9913(21)00245-9
   Google Scholar
• Bolhuis TE, Marsman DE, Den Broeder AA, et al. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial. Lancet Rheumatol. 2023;5(4):e208–e214. doi: 10.1016/S2665-9913(23)00032-2
   PubMedGoogle Scholar
• Toussirot E, Michaud M, Wendling D, et al. Abatacept as adjunctive therapy in refractory polymyalgia rheumatica. J Rheumatol. 2021 Dec;48(12):1888–1889. doi: 10.3899/jrheum.210455
   PubMed Web of Science ®Google Scholar
• Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS (ALORS). https://beta.clinicaltrials.gov/study/NCT03632187
   Google Scholar
• Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica. 2023. https://clinicaltrials.gov/study/NCT05533125
   Google Scholar
• Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse. 2023. https://clinicaltrials.gov/study/NCT05533164
   Google Scholar
• Phase III study of efficacy and safety of secukinumab versus placebo, in combination with Glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR) (REPLENISH). https://beta.clinicaltrials.gov/study/NCT05767034
   Google Scholar
• Kevzara® (sarilumab). Approved by FDA as first and only biologic indicated for patients with polymyalgia rheumatica | regeneron pharmaceuticals inc. https://investor.regeneron.com/news-releases/news-release-details/kevzarar-sarilumab-approved-fda-first-and-only-biologic/.
   Google Scholar
• Moiseev S, Novikov P, Fomin V. Tocilizumab for polymyalgia rheumatica: a first or second line? Ann Rheum Dis. 2016 Aug;75(8):e47. doi: 10.1136/annrheumdis-2016-209596
   PubMed Web of Science ®Google Scholar
• Nepal D, Putman M, Unizony S. Giant cell arteritis and Polymyalgia Rheumatica: treatment approaches and New targets. Rheum Dis Clin North Am. 2023 Aug;49(3):505–521. doi: 10.1016/j.rdc.2023.03.005
   PubMed Web of Science ®Google Scholar
• Ma X, Yang F, Wu J, et al. Efficacy and safety of tofacitinib in patients with Polymyalgia Rheumatica (EAST PMR): an open-label randomized controlled trial. PLOS Med. 2023 Jun 29;20(6):e1004249. doi: 10.1371/journal.pmed.1004249
   PubMed Web of Science ®Google Scholar